Sign up to save your podcasts
Or
Share Managing Toxicities of CDK4/6 Inhibitors in Hormone Positive Breast Cancer - Dr. Stephanie Graff
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Managing Toxicities of CDK4/6 Inhibitors in Hormone Positive Breast Cancer - Dr. Stephanie Graff
In this episode of Oncology Brothers, we dived deep into the world of CDK4-6 inhibitors, focusing on their side effects and management in breast cancer treatment. Joined by an esteemed guest, Dr. Stephanie Graff, a medical breast oncologist from Brown University Health. We explored the side effects and management strategies for three commonly used CDK4/6 inhibitors: ribociclib, abemaciclib, and palbociclib.
Key topics discussed include:
• The evolving role of CDK4/6 inhibitors in early breast cancer and adjuvant settings.
• Detailed management of side effects such as QT prolongation, liver function tests, and diarrhea.
• The importance of shared decision-making with patients regarding treatment options.
• Insights into the latest clinical trial data and its implications for practice.
Whether you're a healthcare professional or someone interested in oncology, this episode provides valuable insights into optimizing patient care while managing the complexities of CDK4-6 inhibitors.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and check out our other episodes for more discussions on oncology treatments and patient management strategies!
#CDK4/6inhibitors #BreastCancer #Ribociclib #Abemaciclib #Palbociclib #OncologyBrothers #SideEffectManagement #HRpositiveBC
View all episodes
By Oncology Brothers
4.8
4040 ratings
In this episode of Oncology Brothers, we dived deep into the world of CDK4-6 inhibitors, focusing on their side effects and management in breast cancer treatment. Joined by an esteemed guest, Dr. Stephanie Graff, a medical breast oncologist from Brown University Health. We explored the side effects and management strategies for three commonly used CDK4/6 inhibitors: ribociclib, abemaciclib, and palbociclib.
Key topics discussed include:
• The evolving role of CDK4/6 inhibitors in early breast cancer and adjuvant settings.
• Detailed management of side effects such as QT prolongation, liver function tests, and diarrhea.
• The importance of shared decision-making with patients regarding treatment options.
• Insights into the latest clinical trial data and its implications for practice.
Whether you're a healthcare professional or someone interested in oncology, this episode provides valuable insights into optimizing patient care while managing the complexities of CDK4-6 inhibitors.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and check out our other episodes for more discussions on oncology treatments and patient management strategies!
#CDK4/6inhibitors #BreastCancer #Ribociclib #Abemaciclib #Palbociclib #OncologyBrothers #SideEffectManagement #HRpositiveBC
More shows like Oncology Brothers: Practice-Changing Cancer Discussions
View all
NEJM This Week
324 Listeners
Journal of Clinical Oncology (JCO) Podcast
40 Listeners
Research To Practice | Oncology Videos
120 Listeners
ASCO Daily News
57 Listeners
Mayo Clinic Talks
295 Listeners
White Coat Investor Podcast
2,439 Listeners
The Curbsiders Internal Medicine Podcast
3,358 Listeners
Core IM | Internal Medicine Podcast
1,145 Listeners
The ONS Podcast
204 Listeners
OncoPharm
187 Listeners
ASCO Guidelines
43 Listeners
OncLive® On Air
22 Listeners
Becker’s Healthcare Podcast
189 Listeners
Oncology Today with Dr Neil Love
59 Listeners
Two Onc Docs
193 Listeners